MMP-1 has been proposed as a biomarker for breast cancer [14,53]; understanding its role in activation of the TGFα/EGFR signal pathway may lead to the use or development of additional targeted agents to suppress this axis, and result in improved treatments for metastatic breast cancer. Here, MMP1 is linked to breast carcinoma.